Links between IBD genetic risk and specific adult tissue lesion contexts help researchers understand which cell types and tissue programs may mediate inherited susceptibility. That can guide future biomarker and...

This real-world, multicenter study suggests risankizumab can induce clinical and steroid-free remission and mucosal healing in many patients with Crohn disease who previously failed advanced therapies, which may be...

Rheumatological EIMs (notably joint inflammation) are frequent in IBD and affect quality of life; inconsistent definitions and lack of validated PROs make it harder for patients and clinicians to understand and compare...

New oral drugs that act mainly in the gut could offer more convenient options and potentially fewer systemic side effects for people with UC or Crohn’s disease. Early clinical signals and a planned Phase 2 trial mean...

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Community and awareness. Open the original article for the...

Faster, more accurate capsule endoscopy reading could shorten diagnostic delays and reduce missed small‑bowel lesions in Crohn’s disease. For busy clinics, an AI assistant could cut review time and help less‑experienced...

Antibiotics can change the gut microbiome in ways that may raise IBD risk or worsen disease for some people. Knowing which antibiotic classes and approaches may be less harmful could help patients and clinicians reduce...

Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of Genetic...

This trial explores whether oral ozanimod can induce and maintain remission in children and adolescents with moderate to severe ulcerative colitis who have not responded to standard therapies. Pediatric-specific evidence...

Cure8 found this source from m.investing.com, but the page could not be read reliably yet. It is tagged for Access, cost, and policy. Open the original article for the full details.

Risk-prediction tools like CDPATH™ could help people with Crohn’s disease and their doctors identify higher or lower short-term risk of complications and guide treatment conversations. This study tests how the tool...

Patients with UC often take multiple medicines that rely on CYP enzymes. This study is checking if afimkibart affects how those drugs are processed, which could matter for safety or dosing if the drug proceeds in...

A validated pre-endoscopic model could help estimate UC disease extent before colonoscopy, aiding clinical triage and planning without replacing endoscopy.

If validated, an early drop in fecal calprotectin could help identify patients on biologic therapy who are likely to achieve mucosal healing without waiting for invasive endoscopy, allowing earlier decisions about...

Digital self-management programs could help people with active IBD build skills to manage symptoms and quality of life between clinic visits. This trial tests whether such a program is feasible, acceptable, and practical...

Early intestinal ultrasound may predict one-year endoscopic remission in Crohn's disease, offering a noninvasive tool to guide treatment decisions and possibly reduce the need for some colonoscopies.

KTS can mimic ulcerative colitis with bloody diarrhea and colonic vascular lesions, so awareness may prevent misdiagnosis and guide appropriate multidisciplinary care. Early recognition can help address bleeding, anemia,...

Perianal fistulizing Crohn's disease is a disabling complication; a subcutaneous form of infliximab could lower treatment burden and expand options if its effectiveness and safety in this specific setting are confirmed.

This global survey shows that people with IBD prioritize symptom relief and psychological well-being over treatment features like administration route or speed of onset. That matters for shared decision-making, trial...

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from msn.com.

If organoid transplantation can be translated to people, it could offer a new way to repair inflamed colonic lining and promote mucosal healing when current therapies are insufficient. The approach also highlights links...

If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.

The 1955 Truelove and Witts criteria do not account for patients already on modern outpatient therapies. Updated consensus criteria could change how ASUC is recognized and triaged in current clinical practice.

A rare but serious colitis linked to ocrelizumab is described and managed successfully with ciclosporin in a steroid‑refractory case; this may be relevant to clinicians caring for patients on B‑cell–depleting therapy.

The study suggests a multi-component herbal formula may affect inflammation, the intestinal barrier, epithelial repair, the gut microbiome, and fecal metabolites in a mouse colitis model—topics relevant to understanding...

This study identifies NR1D1 activation by the experimental drug SR9009 as a potential way to reduce inflammation and improve colon pathology in a mouse model of obesity-associated ulcerative colitis.

Guidelines recommend treating objective inflammation even when symptoms are mild because untreated disease can cause complications; the article describes escalation to risankizumab due to endoscopic inflammation, high...

Based on the title and source metadata, this appears to be a conference abstract related to Inflammatory bowel disease and Research and clinical trials. The original article is from gastroendonews.com.

If confirmed, antibody signatures detectable years before symptoms could help identify people at higher risk for IBD and improve understanding of how the disease begins — a step toward earlier diagnosis or future...

Transition from pediatric to adult IBD care is a high-risk period; structured programs and better communication can improve adherence and reduce relapse and hospitalization risk for young people with IBD.

Real-world data show how mirikizumab performs outside clinical trials, especially in patients previously exposed to multiple advanced therapies. That can help patients and clinicians weigh expectations for effectiveness...

Oat beta-glucan is a dietary fibre with prebiotic properties; the review suggests potential benefits seen in animal studies but shows human evidence is limited. Patients and clinicians may care because dietary fibres are...

Identifying patients at higher risk of hospitalization earlier could help clinicians target monitoring or treatment changes before clinical deterioration. Standard lab reference ranges may miss meaningful within-person...

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from djournal.com.

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Upadacitinib. The original article is from Przeglad gastroenterologiczny.

Methotrexate is commonly used in IBD, often with biologics, but real‑world data on how long patients stay on it, typical dosing, and safety in large contemporary cohorts are limited.

Fear of movement was more common and more severe in people with ulcerative colitis in this study. Addressing kinesiophobia could help increase physical activity and improve function and quality of life for people with...

This study suggests tofacitinib may work quickly as a rescue option for biologic‑naive patients with steroid‑refractory ASUC and that many achieved steroid‑free remission by 24 weeks — information that could matter when...

An externally validated, simple prediction score could help identify patients unlikely to need early aggressive treatment and inform shared decision-making about monitoring and therapy.

This is an official prescribing-label update for an adalimumab biosimilar used to treat Crohn’s disease and ulcerative colitis, including pediatric indications and dosing. Changes to indications or pediatric dosing and...

Life satisfaction and social/work impacts are central to daily functioning for people with IBD. Knowing which social factors relate to lower satisfaction can help patients, caregivers, and clinicians spot who may need...

Dietary therapy (CDED + PEN) was associated with longer remission when families adhered well; since adherence varies, support from a dietitian matters for keeping children in remission.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and JAK inhibitor. The original article is from Journal of Crohn's & colitis.

This paper systematically catalogs drugs that have been reported with new or worsening IBD in two large pharmacovigilance databases. Knowing which medications generate strong reporting signals can help clinicians and...

A patient-centered journey map identifies changing symptom, psychological, and social needs at different stages of Crohn's disease. That can help clinicians and care teams target education, mental-health support, and...

People with ulcerative colitis may be interested because ferulic acid is a plant-derived compound that, in lab and animal studies, appears to reduce gut inflammation, support the intestinal barrier, and positively...

Kidney and urinary problems (acute or chronic kidney injury and kidney stones) occurred in a notable minority of IBD patients in this study and were linked to prior IBD surgery, extensive UC, and cardiometabolic...

Active IBD was linked to higher risk of RSV infection and more severe respiratory outcomes in this large observational study. That could be relevant for prevention and monitoring during periods of active disease.